董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ivan Tornos | 男 | Chairman of the Board and Chief Executive Officer and Director and President | 50 | 1610.66万美元 | 30.38 | 2026-05-22 |
| Sreelakshmi Kolli | 女 | Independent Director | 51 | 39.70万美元 | 0.83 | 2026-05-22 |
| Maria Teresa Hilado | 女 | Independent Director | 61 | 34.31万美元 | 1.16 | 2026-05-22 |
| Syed Jafry | 男 | Independent Director | 62 | 35.26万美元 | 1.54 | 2026-05-22 |
| Devdatt Kurdikar | 男 | Independent Director | 57 | 37.09万美元 | 0.18 | 2026-05-22 |
| Louis A. Shapiro | 男 | Independent Director | 66 | 37.16万美元 | 0.25 | 2026-05-22 |
| Betsy J. Bernard | 女 | Independent Director | 71 | 34.93万美元 | 3.77 | 2026-05-22 |
| Arthur J. Higgins | 男 | Independent Director | 70 | 34.81万美元 | 3.85 | 2026-05-22 |
| Robert A. Hagemann | 男 | Independent Director | 69 | 35.63万美元 | 3.83 | 2026-05-22 |
| Michael J. Farrell | 男 | Independent Director | 54 | 37.04万美元 | 1.91 | 2026-05-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ivan Tornos | 男 | Chairman of the Board and Chief Executive Officer and Director and President | 50 | 1610.66万美元 | 30.38 | 2026-05-22 |
| Wilfred van Zuilen | 男 | Group President, Europe, Middle East and Africa | 56 | 413.94万美元 | 9.06 | 2026-05-22 |
| Paul Stellato | 男 | Interim Chief Financial Officer,Chief Accounting Officer,Controller and Vice President | 51 | 未披露 | 未持股 | 2026-05-22 |
| Kevin Thornal | 男 | Group President, Global Businesses and the Americas | 52 | 621.07万美元 | 未持股 | 2026-05-22 |
| Jehanzeb Noor | 男 | Chief Strategy, Business Development, Innovation and Transformation Officer and Senior Vice President | 44 | 787.42万美元 | 0.02 | 2026-05-22 |
董事简历
中英对照 | 中文 | 英文- Ivan Tornos
-
Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
Ivan Tornos President and Chief Executive Officer of the company and member of the company's Board of Directors since August 2023 and Chairman of the Board since May 2025. Previously, Mr. Tornos served as the Chief Operating Officer of the company since March 2021, as the company's Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the company in November 2018 until December 2019. Prior to joining the company, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility. - Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
- Ivan Tornos President and Chief Executive Officer of the company and member of the company's Board of Directors since August 2023 and Chairman of the Board since May 2025. Previously, Mr. Tornos served as the Chief Operating Officer of the company since March 2021, as the company's Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the company in November 2018 until December 2019. Prior to joining the company, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility.
- Sreelakshmi Kolli
-
Sreelakshmi Kolli，自2023年10月起担任直觉外科公司董事会成员。她目前是全球医疗器械公司Align Technology, Inc.（“Align”）的首席数字官。Kolli女士于2003年6月加入Align，在其任职期间担任过越来越多的职务，负责领导面向客户的应用程序的业务运营和工程。2012年12月晋升为信息技术副总裁，2018年2月晋升为全球信息技术高级副总裁，2020年4月晋升为高级副总裁、首席数字官。Kolli女士还是齐默巴奥米特控股公司的董事会成员。她是Salesforce.com执行顾问委员会的成员，也是旧金山大学信息技术董事会的外部顾问。Kolli女士在印度Trichy的Bharathidasan大学获得了物理学学士学位，并在国立理工学院获得了计算机应用硕士学位。她也是加州斯坦福商学院提供的斯坦福高管项目的毕业生。
Sreelakshmi Kolli,has been a member of Intuitive Surgical, Inc. Board of Directors since October 2023. She is currently chief digital officer of Align Technology, Inc. ("Align"), a global medical device company. Ms. Kolli joined Align in June 2003 and has held positions of increasing responsibility leading business operations and engineering for customer-facing applications during her tenure. She was promoted to vice president, information technology, in December 2012, to senior vice president, global information technology, in February 2018, and to senior vice president, chief digital officer, in April 2020. Ms. Kolli is also a member of the Board of Directors of Zimmer Biomet Holdings, Inc. She is a member of the Executive Advisory Board at Salesforce.com and an external advisor on the Board of Trustees Committee on Information Technology at the University of San Francisco. Ms. Kolli earned a B.S. in physics at Bharathidasan University and an M.S. in computer applications at the National Institute of Technology, both in Trichy, India. She is also a graduate of the Stanford Executive Program offered by the Stanford Graduate School of Business in California. - Sreelakshmi Kolli，自2023年10月起担任直觉外科公司董事会成员。她目前是全球医疗器械公司Align Technology, Inc.（“Align”）的首席数字官。Kolli女士于2003年6月加入Align，在其任职期间担任过越来越多的职务，负责领导面向客户的应用程序的业务运营和工程。2012年12月晋升为信息技术副总裁，2018年2月晋升为全球信息技术高级副总裁，2020年4月晋升为高级副总裁、首席数字官。Kolli女士还是齐默巴奥米特控股公司的董事会成员。她是Salesforce.com执行顾问委员会的成员，也是旧金山大学信息技术董事会的外部顾问。Kolli女士在印度Trichy的Bharathidasan大学获得了物理学学士学位，并在国立理工学院获得了计算机应用硕士学位。她也是加州斯坦福商学院提供的斯坦福高管项目的毕业生。
- Sreelakshmi Kolli,has been a member of Intuitive Surgical, Inc. Board of Directors since October 2023. She is currently chief digital officer of Align Technology, Inc. ("Align"), a global medical device company. Ms. Kolli joined Align in June 2003 and has held positions of increasing responsibility leading business operations and engineering for customer-facing applications during her tenure. She was promoted to vice president, information technology, in December 2012, to senior vice president, global information technology, in February 2018, and to senior vice president, chief digital officer, in April 2020. Ms. Kolli is also a member of the Board of Directors of Zimmer Biomet Holdings, Inc. She is a member of the Executive Advisory Board at Salesforce.com and an external advisor on the Board of Trustees Committee on Information Technology at the University of San Francisco. Ms. Kolli earned a B.S. in physics at Bharathidasan University and an M.S. in computer applications at the National Institute of Technology, both in Trichy, India. She is also a graduate of the Stanford Executive Program offered by the Stanford Graduate School of Business in California.
- Maria Teresa Hilado
-
Maria Teresa Hilado，担任全球制药公司Allergan plc的执行副总裁兼首席财务官（2014年12月至2018年2月退休）。在加入Allergan之前，Hilado女士从2009年到2014年担任百事可乐公司（PepsiCo Inc.）的财务高级副总裁和财务主管，负责全球运营项目，包括资本市场、资金管理、国际财务、养老金、保险以及全球采购资金。她此前曾担任Schering-Plough Corp.的副总裁兼财务主管（从2008年到2009年），也曾任职通用汽车公司（General Motors Co.）17年以上，担任领导职务，并不断增加责任，包括助理财务主管（从2006年到2008年）、GMAC Commercial Finance LLC的首席财务官（从2001年到2005年）。她的职业生涯始于菲律宾马尼拉的Far East Bank and Trust Co.。Hilado女士获得了菲律宾马尼拉雅典耀大学的管理工程学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
Maria Teresa Hilado served as Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo, Inc. from 2009 until 2014. She previoly served as Vice President and Treasurer for Schering Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer and CFO, GMAC Commercial Finance. Ms. Hilado received a bachelor's degree in management engineering from Ateneo de Manila University in the Philippines, and a master of biness administration from the Darden School of Biness at the University of Virginia. - Maria Teresa Hilado，担任全球制药公司Allergan plc的执行副总裁兼首席财务官（2014年12月至2018年2月退休）。在加入Allergan之前，Hilado女士从2009年到2014年担任百事可乐公司（PepsiCo Inc.）的财务高级副总裁和财务主管，负责全球运营项目，包括资本市场、资金管理、国际财务、养老金、保险以及全球采购资金。她此前曾担任Schering-Plough Corp.的副总裁兼财务主管（从2008年到2009年），也曾任职通用汽车公司（General Motors Co.）17年以上，担任领导职务，并不断增加责任，包括助理财务主管（从2006年到2008年）、GMAC Commercial Finance LLC的首席财务官（从2001年到2005年）。她的职业生涯始于菲律宾马尼拉的Far East Bank and Trust Co.。Hilado女士获得了菲律宾马尼拉雅典耀大学的管理工程学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
- Maria Teresa Hilado served as Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo, Inc. from 2009 until 2014. She previoly served as Vice President and Treasurer for Schering Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer and CFO, GMAC Commercial Finance. Ms. Hilado received a bachelor's degree in management engineering from Ateneo de Manila University in the Philippines, and a master of biness administration from the Darden School of Biness at the University of Virginia.
- Syed Jafry
-
Syed Jafry自2017年9月起担任Thermo Fisher Scientific Inc.地区高级副总裁兼总裁。他负责美国以外的所有业务地区。他于2005年3月加入Thermo Fisher Scientific，并在被任命为当前职位之前担任过许多职责不断增加的职务。Jafry先生的职业生涯始于伦敦的Glaxo Pharmaceuticals。加入Thermo Fisher Scientific之前，他在通用电气（General Electric）任职18年，在美国，荷兰，瑞士和中国担任商业，产品管理和一般管理职务，最近担任GE Sensing Asia总裁。Jafry先生拥有巴基斯坦拉合尔大学的机械工程学士学位，马萨诸塞大学的机械工程硕士学位和哈佛大学扩展学院的市场营销和管理硕士学位。
Syed Jafry,Senior Vice President and President, Regions of Thermo Fisher Scientific Inc. from September 2017 through his scheduled retirement announced for March 31 2022. Mr. Jafry is responsible for all business geographies outside the U.S. He joined Thermo Fisher Scientific in March 2005 and served in numerous roles of increasing responsibility prior to being appointed to his current position. Mr. Jafry started his career at Glaxo Pharmaceuticals in London. Prior to joining Thermo Fisher Scientific, he served for 18 years at General Electric, where he held commercial, product management and general management roles in the U.S., Netherlands, Switzerland and China, most recently serving as President of GE Sensing Asia. Mr. Jafry holds a Bachelor's degree in Mechanical Engineering from Lahore University in Pakistan, a Master's degree in Mechanical Engineering from the University of Massachusetts and a Master's certificate in Marketing and Management from Harvard University Extension School. - Syed Jafry自2017年9月起担任Thermo Fisher Scientific Inc.地区高级副总裁兼总裁。他负责美国以外的所有业务地区。他于2005年3月加入Thermo Fisher Scientific，并在被任命为当前职位之前担任过许多职责不断增加的职务。Jafry先生的职业生涯始于伦敦的Glaxo Pharmaceuticals。加入Thermo Fisher Scientific之前，他在通用电气（General Electric）任职18年，在美国，荷兰，瑞士和中国担任商业，产品管理和一般管理职务，最近担任GE Sensing Asia总裁。Jafry先生拥有巴基斯坦拉合尔大学的机械工程学士学位，马萨诸塞大学的机械工程硕士学位和哈佛大学扩展学院的市场营销和管理硕士学位。
- Syed Jafry,Senior Vice President and President, Regions of Thermo Fisher Scientific Inc. from September 2017 through his scheduled retirement announced for March 31 2022. Mr. Jafry is responsible for all business geographies outside the U.S. He joined Thermo Fisher Scientific in March 2005 and served in numerous roles of increasing responsibility prior to being appointed to his current position. Mr. Jafry started his career at Glaxo Pharmaceuticals in London. Prior to joining Thermo Fisher Scientific, he served for 18 years at General Electric, where he held commercial, product management and general management roles in the U.S., Netherlands, Switzerland and China, most recently serving as President of GE Sensing Asia. Mr. Jafry holds a Bachelor's degree in Mechanical Engineering from Lahore University in Pakistan, a Master's degree in Mechanical Engineering from the University of Massachusetts and a Master's certificate in Marketing and Management from Harvard University Extension School.
- Devdatt Kurdikar
-
Devdatt Kurdikar是Embecta的总裁兼首席执行官。此前，他曾担任BD公司糖尿病护理全球总裁。在此之前，他曾担任Cardiac Science Corporation（“CSC”）的总裁兼首席执行官，该公司是公共准入市场自动体外除颤器制造和营销的全球领导者。CSC通过破产程序被一家私募股权公司收购，在Kurdikar先生的领导下，CSC恢复了盈利增长，并成功出售给ZOLL Medical。在此之前，Kurdikar先生是Boston Scientific泌尿科和盆腔健康部门的男性健康副总裁兼总经理。他曾在American Medical Systems（“AMS”）担任相同的职务，并领导Men’s Health业务通过分拆和出售给Boston Scientific，在那里他领导业务通过整合到Boston Scientific。加入AMS之前，他曾担任Baxter International Inc.（“Baxter”）的营销副总裁，在那里他参与了推动市场准入的全球商业计划，并曾担任美国地区输液系统业务的营销副总裁。在他任职百特的11年里，Kurdikar先生在财务、战略和整合、研发计划和运营方面担任领导职务。他的职业生涯始于孟山都公司的高级研究工程师。Kurdikar拥有孟买大学（印度）化学工程学士学位。他获得Washington State大学的化学工程硕士学位，Purdue大学的化学工程博士学位，以及Washington大学的工商管理硕士学位。
Devdatt Kurdikar is the President and Chief Executive Officer of Embecta. Previoly, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation ("CSC"), a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Mr. Kurdikar's leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical. Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific. Mr. Kurdikar was in the same role at American Medical Systems ("AMS") and led the Men's Health biness through a carve out and sale to Boston Scientific, where Mr. Kurdikar led the biness through its integration into Boston Scientific. Before joining AMS, Mr. Kurdikar served as Vice President, Marketing, at Baxter, where he worked on a global commercial initiative to drive market access, and was previoly Vice President, Marketing, for the Infion Systems biness for the U.S. region. In his 11 years with Baxter, Mr. Kurdikar held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company. - Devdatt Kurdikar是Embecta的总裁兼首席执行官。此前，他曾担任BD公司糖尿病护理全球总裁。在此之前，他曾担任Cardiac Science Corporation（“CSC”）的总裁兼首席执行官，该公司是公共准入市场自动体外除颤器制造和营销的全球领导者。CSC通过破产程序被一家私募股权公司收购，在Kurdikar先生的领导下，CSC恢复了盈利增长，并成功出售给ZOLL Medical。在此之前，Kurdikar先生是Boston Scientific泌尿科和盆腔健康部门的男性健康副总裁兼总经理。他曾在American Medical Systems（“AMS”）担任相同的职务，并领导Men’s Health业务通过分拆和出售给Boston Scientific，在那里他领导业务通过整合到Boston Scientific。加入AMS之前，他曾担任Baxter International Inc.（“Baxter”）的营销副总裁，在那里他参与了推动市场准入的全球商业计划，并曾担任美国地区输液系统业务的营销副总裁。在他任职百特的11年里，Kurdikar先生在财务、战略和整合、研发计划和运营方面担任领导职务。他的职业生涯始于孟山都公司的高级研究工程师。Kurdikar拥有孟买大学（印度）化学工程学士学位。他获得Washington State大学的化学工程硕士学位，Purdue大学的化学工程博士学位，以及Washington大学的工商管理硕士学位。
- Devdatt Kurdikar is the President and Chief Executive Officer of Embecta. Previoly, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation ("CSC"), a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Mr. Kurdikar's leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical. Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific. Mr. Kurdikar was in the same role at American Medical Systems ("AMS") and led the Men's Health biness through a carve out and sale to Boston Scientific, where Mr. Kurdikar led the biness through its integration into Boston Scientific. Before joining AMS, Mr. Kurdikar served as Vice President, Marketing, at Baxter, where he worked on a global commercial initiative to drive market access, and was previoly Vice President, Marketing, for the Infion Systems biness for the U.S. region. In his 11 years with Baxter, Mr. Kurdikar held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
- Louis A. Shapiro
-
Louis A. Shapiro，他于2006年10月加入HSS担任总裁兼首席执行官，并于2023年10月退休。在加入HSS之前，他从2002年到2006年在Geisinger Health System工作，担任越来越多的领导职务，并最终晋升为临床企业的执行副总裁兼首席运营官。从1999年到2002年，他担任McKinsey & Co.的高级医疗保健专家和顾问，并从1983年到1999年在其他医院和卫生系统担任职务。他还曾担任RightMove Health董事会的创始成员，Medical indemnity Assurance Company的总裁，以及the Greater New York Hospital Association的董事会主席，此外在他的职业生涯中还担任过许多其他董事会和顾问职位。他拥有Pittsburgh大学的心理学学士学位和Pittsburgh Graduate School of Public health大学的卫生管理硕士学位。
Louis A. Shapiro served as President and Chief Executive Officer of the Hospital for Special Surgery ("HSS"), a leading academic medical center focused on musculoskeletal health, from 2006 until his retirement in 2023. Prior to joining HSS, Mr. Shapiro worked at Geisinger Health System from 2002 to 2006, serving in roles with increasing leadership scope and ultimately advancing to Executive Vice President and Chief Operating Officer of the Clinical Enterprise. From 1999 to 2002, he served as a senior healthcare expert and consultant at McKinsey & Co. Prior to McKinsey, he held positions in other hospitals and health systems from 1983 through 1999. Since October 2023, Mr. Shapiro has served as a Senior Advisor to General Atlantic, a private equity firm, and on the board of certain of their healthcare focused portfolio companies. Additionally, Mr. Shapiro serves in numerous advisory capacities and board positions at other privately held organizations. He is currently a director of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH). - Louis A. Shapiro，他于2006年10月加入HSS担任总裁兼首席执行官，并于2023年10月退休。在加入HSS之前，他从2002年到2006年在Geisinger Health System工作，担任越来越多的领导职务，并最终晋升为临床企业的执行副总裁兼首席运营官。从1999年到2002年，他担任McKinsey & Co.的高级医疗保健专家和顾问，并从1983年到1999年在其他医院和卫生系统担任职务。他还曾担任RightMove Health董事会的创始成员，Medical indemnity Assurance Company的总裁，以及the Greater New York Hospital Association的董事会主席，此外在他的职业生涯中还担任过许多其他董事会和顾问职位。他拥有Pittsburgh大学的心理学学士学位和Pittsburgh Graduate School of Public health大学的卫生管理硕士学位。
- Louis A. Shapiro served as President and Chief Executive Officer of the Hospital for Special Surgery ("HSS"), a leading academic medical center focused on musculoskeletal health, from 2006 until his retirement in 2023. Prior to joining HSS, Mr. Shapiro worked at Geisinger Health System from 2002 to 2006, serving in roles with increasing leadership scope and ultimately advancing to Executive Vice President and Chief Operating Officer of the Clinical Enterprise. From 1999 to 2002, he served as a senior healthcare expert and consultant at McKinsey & Co. Prior to McKinsey, he held positions in other hospitals and health systems from 1983 through 1999. Since October 2023, Mr. Shapiro has served as a Senior Advisor to General Atlantic, a private equity firm, and on the board of certain of their healthcare focused portfolio companies. Additionally, Mr. Shapiro serves in numerous advisory capacities and board positions at other privately held organizations. He is currently a director of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH).
- Betsy J. Bernard
-
Betsy J. Bernard从2007年5月21日开始担任候补首席董事。Bernard女士从2002年10月到2003年12月担任 AT&T的总裁，她在该公司领导AT&T业务部的超过50000位雇员，之后是将近27 0亿美元的机构，其服务400万商业客户。她从2001年至2002年担任 AT&T消费者部门的首席执行官，该部门服务大约4000万消费者，并于2002年为AT&T贡献了115亿美元的常规收入。她担任消费者与小型业务分部的负责人，从2000年至2001年，担任Qwest Communications全国大众市场部的执行副总裁，并负责管理美国西部地区的所有零售市场，从1998年至2000年担任零售部的执行副总裁。
Betsy J. Bernard,President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University's Sloan Fellowship Program. - Betsy J. Bernard从2007年5月21日开始担任候补首席董事。Bernard女士从2002年10月到2003年12月担任 AT&T的总裁，她在该公司领导AT&T业务部的超过50000位雇员，之后是将近27 0亿美元的机构，其服务400万商业客户。她从2001年至2002年担任 AT&T消费者部门的首席执行官，该部门服务大约4000万消费者，并于2002年为AT&T贡献了115亿美元的常规收入。她担任消费者与小型业务分部的负责人，从2000年至2001年，担任Qwest Communications全国大众市场部的执行副总裁，并负责管理美国西部地区的所有零售市场，从1998年至2000年担任零售部的执行副总裁。
- Betsy J. Bernard,President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University's Sloan Fellowship Program.
- Arthur J. Higgins
-
Arthur J. Higgins，自2010年6月以来担任The Blackstone Group的顾问。在此之前，他于2006年1月至2010年5月间担任Bayer HealthCare AG的董事会主席，2004年7月至2010年5月间担任Bayer HealthCare Executive Committee的主席。此前，他曾于2001至2004年间担任Enzon Pharmaceuticals Inc.的董事长兼总裁。更早些时候，他效力于Abbott Laboratories长达14年之久，最近于1998至2001年间任其医药产品事业部总监。他是Pharmaceutical Research and Manufacturers of America PhRMA的前董事会成员，是国际制药商协会联合会（IFPMA）的前成员，也是欧洲制药工业协会联盟（EFPIA）的前主席。他是Ecolab Inc.和 Endo International plc的董事，也曾担任Resverlogix Corp.的董事。他毕业于苏格兰斯特拉斯克莱德大学，并获得生物化学理学学士学位。
Arthur J. Higgins,Operating Advisor to Abu Dhabi Investment Authority ("ADIA"), a sovereign globally-diversified wealth fund of the Government of the Emirate of Abu Dhabi. Prior to joining ADIA, Mr. Higgins served as Consultant to Blackstone Healthcare Partners of The Blackstone Group from June 2010 until June 2021. He also served as non-executive chairman of the board of Assertio Holdings, Inc., successor issuer to Assertio Therapeutics, Inc., from May 2020 until December 2020. Prior to that, he served as President, Chief Executive Officer and a member of the board of directors of Assertio Therapeutics, Inc. from March 2017 until its merger with Zyla Life Sciences in May 2020. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America ("PHRMA"), Council member of the International Federation of Pharmaceutical Manufacturers ("IFPMA") and President of the European Federation of Pharmaceutical Industries Association ("EFPIA"). He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry. - Arthur J. Higgins，自2010年6月以来担任The Blackstone Group的顾问。在此之前，他于2006年1月至2010年5月间担任Bayer HealthCare AG的董事会主席，2004年7月至2010年5月间担任Bayer HealthCare Executive Committee的主席。此前，他曾于2001至2004年间担任Enzon Pharmaceuticals Inc.的董事长兼总裁。更早些时候，他效力于Abbott Laboratories长达14年之久，最近于1998至2001年间任其医药产品事业部总监。他是Pharmaceutical Research and Manufacturers of America PhRMA的前董事会成员，是国际制药商协会联合会（IFPMA）的前成员，也是欧洲制药工业协会联盟（EFPIA）的前主席。他是Ecolab Inc.和 Endo International plc的董事，也曾担任Resverlogix Corp.的董事。他毕业于苏格兰斯特拉斯克莱德大学，并获得生物化学理学学士学位。
- Arthur J. Higgins,Operating Advisor to Abu Dhabi Investment Authority ("ADIA"), a sovereign globally-diversified wealth fund of the Government of the Emirate of Abu Dhabi. Prior to joining ADIA, Mr. Higgins served as Consultant to Blackstone Healthcare Partners of The Blackstone Group from June 2010 until June 2021. He also served as non-executive chairman of the board of Assertio Holdings, Inc., successor issuer to Assertio Therapeutics, Inc., from May 2020 until December 2020. Prior to that, he served as President, Chief Executive Officer and a member of the board of directors of Assertio Therapeutics, Inc. from March 2017 until its merger with Zyla Life Sciences in May 2020. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America ("PHRMA"), Council member of the International Federation of Pharmaceutical Manufacturers ("IFPMA") and President of the European Federation of Pharmaceutical Industries Association ("EFPIA"). He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry.
- Robert A. Hagemann
-
Robert A. Hagemann， Quest Diagnostics Incorporated的高级副总裁兼首席财务官，直到2013年7月退休。Hagemann先生于1992年加入Corning Life Sciences, Inc.（Quest Diagnostics的前母公司Corning的子公司），并在1998年被任命为Quest Diagnostics的首席财务官之前担任越来越重要的职务。加入Corning之前，他曾在Prime Hospitality， Inc.和Crompton & Knowles， Inc.担任高级财务职位。他还曾受雇于Arthur Young & Co. （Ernst & Young的前身公司）。他持有Rider大学的会计学士学位和Seton Hall大学的工商管理硕士学位。
Robert A. Hagemann,Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics' former parent company, Corning Incorporated, in 1992 and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University. - Robert A. Hagemann， Quest Diagnostics Incorporated的高级副总裁兼首席财务官，直到2013年7月退休。Hagemann先生于1992年加入Corning Life Sciences, Inc.（Quest Diagnostics的前母公司Corning的子公司），并在1998年被任命为Quest Diagnostics的首席财务官之前担任越来越重要的职务。加入Corning之前，他曾在Prime Hospitality， Inc.和Crompton & Knowles， Inc.担任高级财务职位。他还曾受雇于Arthur Young & Co. （Ernst & Young的前身公司）。他持有Rider大学的会计学士学位和Seton Hall大学的工商管理硕士学位。
- Robert A. Hagemann,Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics' former parent company, Corning Incorporated, in 1992 and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University.
- Michael J. Farrell
-
Michael J. Farrell，他一直担任ResMed董事（自2013年3月1日以来）。他一直担任ResMed的首席执行官和董事（2013年3月1日以来）。此前，他曾担任ResMed的美洲总裁（2011年5月以来）。他此前曾担任ResMed的战略业务单元的高级副总裁（从2007年7月到2011年5月）、ResMed的副总裁，负责美洲营销（从2005年6月到2007年7月），以及ResMed的副总裁，负责业务发展。他于2000年9月加入ResMed公司。此前，他曾担任Arthur D. Little、Genzyme Corporation、The Dow Chemical Company、BHP Billiton的管理咨询和生物技术、化工和钢铁制造业的职务。他任职于the La Jolla Playhouse和圣地亚哥the New Children's Museum的董事会。他持有新南威尔士大学的工程学士学位（一等荣誉）、麻省理工学院（Massachusetts Institute of Technology）的化学工程理学硕士学位，以及史隆管理学院 （ MIT Sloan School of Management）的工商管理硕士学位。
Michael J. Farrell,Chief Executive Officer of ResMed Inc. since March 2013 and Chairman of ResMed Inc. since January 2023. Prior to his appointment as Chief Executive Officer, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Sanofi Genzyme, Dow Chemical and BHP. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management. - Michael J. Farrell，他一直担任ResMed董事（自2013年3月1日以来）。他一直担任ResMed的首席执行官和董事（2013年3月1日以来）。此前，他曾担任ResMed的美洲总裁（2011年5月以来）。他此前曾担任ResMed的战略业务单元的高级副总裁（从2007年7月到2011年5月）、ResMed的副总裁，负责美洲营销（从2005年6月到2007年7月），以及ResMed的副总裁，负责业务发展。他于2000年9月加入ResMed公司。此前，他曾担任Arthur D. Little、Genzyme Corporation、The Dow Chemical Company、BHP Billiton的管理咨询和生物技术、化工和钢铁制造业的职务。他任职于the La Jolla Playhouse和圣地亚哥the New Children's Museum的董事会。他持有新南威尔士大学的工程学士学位（一等荣誉）、麻省理工学院（Massachusetts Institute of Technology）的化学工程理学硕士学位，以及史隆管理学院 （ MIT Sloan School of Management）的工商管理硕士学位。
- Michael J. Farrell,Chief Executive Officer of ResMed Inc. since March 2013 and Chairman of ResMed Inc. since January 2023. Prior to his appointment as Chief Executive Officer, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Sanofi Genzyme, Dow Chemical and BHP. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management.
高管简历
中英对照 | 中文 | 英文- Ivan Tornos
Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
Ivan Tornos President and Chief Executive Officer of the company and member of the company's Board of Directors since August 2023 and Chairman of the Board since May 2025. Previously, Mr. Tornos served as the Chief Operating Officer of the company since March 2021, as the company's Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the company in November 2018 until December 2019. Prior to joining the company, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility.- Ivan Tornos于2018年11月加入Zimmer Biomet，担任骨科集团总裁，并于2019年12月被任命为全球业务和美洲集团总裁。在加入Zimmer Biomet之前，Tornos先生自2017年6月起担任Becton，Dickinson和“ BD”公司（以及之前的CR Bard，Inc.（“ Bard”））全球泌尿科，医学和重症监护部门的全球总裁。直到2018年10月。从2017年6月直到BD在2017年12月收购Bard，Tornos先生还继续担任Bard欧洲，中东和非洲地区总裁，并于2013年9月被任命为该职位。Tornos先生于2011年8月加入Bard，在被任命为EMEA总裁之前，他曾担任副总裁兼总经理，领导Bard在南欧，中欧以及中东和非洲的新兴市场区域的业务。在加入Bard之前，Tornos先生于2009年4月至2011年8月担任Covidien International美洲制药和医疗/影像业务部门的副总裁兼总经理。在此之前，他曾担任Baxter International业务发展和战略国际副总裁。 Inc.从2008年7月至2009年4月，在此之前，Tornos先生在强生公司任职11年，担任越来越重的职务。
- Ivan Tornos President and Chief Executive Officer of the company and member of the company's Board of Directors since August 2023 and Chairman of the Board since May 2025. Previously, Mr. Tornos served as the Chief Operating Officer of the company since March 2021, as the company's Group President, Global Businesses and the Americas from December 2019 until March 2021, and as Group President, Orthopedics from joining the company in November 2018 until December 2019. Prior to joining the company, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company ("BD") (and previously, C. R. Bard, Inc. ("Bard")) from June 2017 until October 2018. From June 2017 until BD's acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, EMEA of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard's business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility.
- Wilfred van Zuilen
Wilfred van Zuilen 于 2021 年 6 月被任命为欧洲、中东和非洲总裁。在加入 Zimmer Biomet 之前，van Zuilen 先生曾在 Medtronic plc 担任过多个职务，包括 2020 年 10 月至 2021 年 5 月担任西北欧副总裁 2017 年 2 月至 2020 年 9 月担任欧洲、中东和非洲地区修复疗法集团副总裁，并于 2011 年 10 月至 2017 年 1 月担任外科解决方案集团欧洲先进外科技术副总裁。1998 年 1 月之前，他在 Medtronic plc 担任过其他职务，职责不断增加。 加入美敦力后，他在医疗销售领域工作了五年多，最近在 Baxter BV Edwards Life Sciences 任职。
Wilfred van Zuilen was appointed Group President, Europe, Middle East and Africa in September 2023, after having served as President, Europe, Middle East and Africa since joining the Company in June 2021. He is responsible for the sales, marketing and distribution of products, services and solutions in the Europe, Middle East and Africa region. Prior to joining Zimmer Biomet, Mr. van Zuilen served in vario roles for Medtronic plc, including as Vice President, North stern Europe from October 2020 to May 2021, as Vice President, Restorative Therapies Group EMEA from February 2017 through September 2020, and as Vice President, Advanced Surgical Technologies Europe, Surgical Solution Group, from October 2011 through January 2017. He served in other roles of increasing responsibility with Medtronic plc through January 1998. Before joining Medtronic, he spent more than five years in medical sales, most recently with Baxter BV (Edwards Lifesciences).- Wilfred van Zuilen 于 2021 年 6 月被任命为欧洲、中东和非洲总裁。在加入 Zimmer Biomet 之前，van Zuilen 先生曾在 Medtronic plc 担任过多个职务，包括 2020 年 10 月至 2021 年 5 月担任西北欧副总裁 2017 年 2 月至 2020 年 9 月担任欧洲、中东和非洲地区修复疗法集团副总裁，并于 2011 年 10 月至 2017 年 1 月担任外科解决方案集团欧洲先进外科技术副总裁。1998 年 1 月之前，他在 Medtronic plc 担任过其他职务，职责不断增加。 加入美敦力后，他在医疗销售领域工作了五年多，最近在 Baxter BV Edwards Life Sciences 任职。
- Wilfred van Zuilen was appointed Group President, Europe, Middle East and Africa in September 2023, after having served as President, Europe, Middle East and Africa since joining the Company in June 2021. He is responsible for the sales, marketing and distribution of products, services and solutions in the Europe, Middle East and Africa region. Prior to joining Zimmer Biomet, Mr. van Zuilen served in vario roles for Medtronic plc, including as Vice President, North stern Europe from October 2020 to May 2021, as Vice President, Restorative Therapies Group EMEA from February 2017 through September 2020, and as Vice President, Advanced Surgical Technologies Europe, Surgical Solution Group, from October 2011 through January 2017. He served in other roles of increasing responsibility with Medtronic plc through January 1998. Before joining Medtronic, he spent more than five years in medical sales, most recently with Baxter BV (Edwards Lifesciences).
- Paul Stellato
Paul Stellato，于2022年5月被任命为副总裁、财务总监和首席会计官。此前，他曾于2019年3月至2022年4月在全球水技术产品和服务提供商Xylem Inc.（“Xylom”）担任全球商业服务部财务副总裁。他于2011年10月从ITT公司（“ITT”）分拆后加入Xylem，并于2017年8月担任Xylem财务、财务规划和分析副总裁。自2016年8月起担任临时公司财务总监后，他于2017年8月晋升为副总裁、财务总监和首席会计官，并于2019年3月成为全球业务服务部财务副总裁。在2011年10月Xylem从ITT分拆之前，Stellato先生于2003年5月开始在ITT任职，最近担任过ITT的总审计师，在此之前担任过投资者关系经理。他在安永会计师事务所（Ernst&Young LLP）和安达信会计师事务所（Arthur Andersen LLP）开始公共会计职业生涯，是一名注册会计师。
Paul Stellato was appointed Vice President, Controller and Chief Accounting Officer in May 2022. Previoly, he served as Vice President Finance, Global Biness Services from March 2019 through April 2022, with Xylem Inc. ("Xylem"), a global provider of water technology products and services. He joined Xylem upon its spinoff from ITT Corporation ("ITT") in October 2011 and served as Xylem's Vice President Finance, Financial Planning and Analysis through August 2017. He was promoted to Vice President, Controller and Chief Accounting Officer in August 2017 after serving as Interim Corporate Controller starting in August 2016, and became Vice President Finance, Global Biness Services in March 2019. Prior to Xylem's spinoff from ITT in October 2011, Mr. Stellato served with ITT beginning in May 2003, having served most recently as ITT's General Auditor and prior to that, as Manager Investor Relations. He began his career in public accounting with Ernst & Young LLP and Arthur Andersen LLP and is a certified public accountant.- Paul Stellato，于2022年5月被任命为副总裁、财务总监和首席会计官。此前，他曾于2019年3月至2022年4月在全球水技术产品和服务提供商Xylem Inc.（“Xylom”）担任全球商业服务部财务副总裁。他于2011年10月从ITT公司（“ITT”）分拆后加入Xylem，并于2017年8月担任Xylem财务、财务规划和分析副总裁。自2016年8月起担任临时公司财务总监后，他于2017年8月晋升为副总裁、财务总监和首席会计官，并于2019年3月成为全球业务服务部财务副总裁。在2011年10月Xylem从ITT分拆之前，Stellato先生于2003年5月开始在ITT任职，最近担任过ITT的总审计师，在此之前担任过投资者关系经理。他在安永会计师事务所（Ernst&Young LLP）和安达信会计师事务所（Arthur Andersen LLP）开始公共会计职业生涯，是一名注册会计师。
- Paul Stellato was appointed Vice President, Controller and Chief Accounting Officer in May 2022. Previoly, he served as Vice President Finance, Global Biness Services from March 2019 through April 2022, with Xylem Inc. ("Xylem"), a global provider of water technology products and services. He joined Xylem upon its spinoff from ITT Corporation ("ITT") in October 2011 and served as Xylem's Vice President Finance, Financial Planning and Analysis through August 2017. He was promoted to Vice President, Controller and Chief Accounting Officer in August 2017 after serving as Interim Corporate Controller starting in August 2016, and became Vice President Finance, Global Biness Services in March 2019. Prior to Xylem's spinoff from ITT in October 2011, Mr. Stellato served with ITT beginning in May 2003, having served most recently as ITT's General Auditor and prior to that, as Manager Investor Relations. He began his career in public accounting with Ernst & Young LLP and Arthur Andersen LLP and is a certified public accountant.
- Kevin Thornal
Kevin Thornal，自2023年4月起担任Nevro Corp.的总裁兼首席执行官，并自2023年5月起担任其董事会成员，直到2025年4月被Globus Medical， Inc.收购完成。此前，他从2022年4月至2023年4月担任Hologic， Inc.（“Hologic”）的全球诊断解决方案集团总裁。从2014年到2023年4月，Thornal先生在Hologic担任多个领导职位，职责不断提升。在加入Hologic之前，从2004年到2014年，Thornal先生在Stryker Corp.担任销售、营销和业务发展方面的多个职位。
Kevin Thornal joined the company as Group President, Global Businesses and the Americas, effective July 1, 2025. Prior to joining the company, Mr. Thornal served as President and Chief Executive Officer of Nevro Corp. from April 2023, and as a member of its Board of Directors from May 2023, until the completion of its acquisition by Globus Medical, Inc. in April 2025. He previously served as the Group President of Global Diagnostic Solutions at Hologic, Inc. from April 2022 to April 2023. Mr. Thornal served in several leadership positions with increasing levels of responsibility at Hologic from 2014 to April 2023. Prior to Hologic, Mr. Thornal held several roles of increasing responsibility at Stryker Corp. from 2004 to 2014 in sales, marketing, and business development.- Kevin Thornal，自2023年4月起担任Nevro Corp.的总裁兼首席执行官，并自2023年5月起担任其董事会成员，直到2025年4月被Globus Medical， Inc.收购完成。此前，他从2022年4月至2023年4月担任Hologic， Inc.（“Hologic”）的全球诊断解决方案集团总裁。从2014年到2023年4月，Thornal先生在Hologic担任多个领导职位，职责不断提升。在加入Hologic之前，从2004年到2014年，Thornal先生在Stryker Corp.担任销售、营销和业务发展方面的多个职位。
- Kevin Thornal joined the company as Group President, Global Businesses and the Americas, effective July 1, 2025. Prior to joining the company, Mr. Thornal served as President and Chief Executive Officer of Nevro Corp. from April 2023, and as a member of its Board of Directors from May 2023, until the completion of its acquisition by Globus Medical, Inc. in April 2025. He previously served as the Group President of Global Diagnostic Solutions at Hologic, Inc. from April 2022 to April 2023. Mr. Thornal served in several leadership positions with increasing levels of responsibility at Hologic from 2014 to April 2023. Prior to Hologic, Mr. Thornal held several roles of increasing responsibility at Stryker Corp. from 2004 to 2014 in sales, marketing, and business development.
- Jehanzeb Noor
Jehanzeb Noor于2026年1月被任命为高级副总裁、首席战略、创新和转型官，此前他于2025年3月被任命为高级副总裁、首席战略、创新和Biness发展官。在其职位上，他负责领导战略制定和执行；监督并购的各个方面；确定短期和长期的有机和无机增长机会；并领导企业范围的转型。此外，他还监督研究和产品开发组织，包括新产品和服务开发、伙伴关系和生态系统开发以及平台技术。在2025年3月加入齐默巴奥米特控之前，Noor先生于2022年8月开始担任Trivium欧洲、非洲和亚洲总裁兼董事总经理，并于2019年7月至2022年1月担任Smiths Medical的首席执行官。他还曾在Amcor、麦肯锡（合伙人）、福特汽车公司和Constellation Energy商品集团担任越来越重要的职务。Noor先生拥有产品设计和运营管理FOC理学硕士学位、金融学理学学士学位和机械工程学理学学士学位，所有这些都来自马萨诸塞州理工学院。
Jehanzeb Noor joined the company as Senior Vice President, Chief Strategy, Business Development, Innovation and Transformation Officer in March 2025. Prior to that, he served as President and Managing Director for Europe, Africa, and Asia at Trivium. Prior to that, he was CEO of Smiths Medical, and before that held roles of increasing responsibility at Amcor, McKinsey (Partner), Ford Motor Company and ConstellationEnergy Commodities Group.- Jehanzeb Noor于2026年1月被任命为高级副总裁、首席战略、创新和转型官，此前他于2025年3月被任命为高级副总裁、首席战略、创新和Biness发展官。在其职位上，他负责领导战略制定和执行；监督并购的各个方面；确定短期和长期的有机和无机增长机会；并领导企业范围的转型。此外，他还监督研究和产品开发组织，包括新产品和服务开发、伙伴关系和生态系统开发以及平台技术。在2025年3月加入齐默巴奥米特控之前，Noor先生于2022年8月开始担任Trivium欧洲、非洲和亚洲总裁兼董事总经理，并于2019年7月至2022年1月担任Smiths Medical的首席执行官。他还曾在Amcor、麦肯锡（合伙人）、福特汽车公司和Constellation Energy商品集团担任越来越重要的职务。Noor先生拥有产品设计和运营管理FOC理学硕士学位、金融学理学学士学位和机械工程学理学学士学位，所有这些都来自马萨诸塞州理工学院。
- Jehanzeb Noor joined the company as Senior Vice President, Chief Strategy, Business Development, Innovation and Transformation Officer in March 2025. Prior to that, he served as President and Managing Director for Europe, Africa, and Asia at Trivium. Prior to that, he was CEO of Smiths Medical, and before that held roles of increasing responsibility at Amcor, McKinsey (Partner), Ford Motor Company and ConstellationEnergy Commodities Group.